TLR2 and hepatocellular carcinoma: Li and colleagues found that the molecule Pam3CSK4, an agonist of Toll-like receptor 2 (TLR2), injected into mice inhibited tumour growth and reduced myeloid-derived suppressor cells (MDSCs), thereby attenuating HCC progression [99].